The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
作者信息
Hutchison J C, Wilkinson W H
出版信息
Atherosclerosis. 1973 Nov-Dec;18(3):353-62. doi: 10.1016/0021-9150(73)90065-8.
PMID:4584481
Abstract
摘要
相似文献
1
The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
Atherosclerosis. 1973 Nov-Dec;18(3):353-62. doi: 10.1016/0021-9150(73)90065-8.
2
Hypolipidemic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate).
Clin Pharmacol Ther. 1971 May-Jun;12(3):517-24. doi: 10.1002/cpt1971123517.
3
[First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
Verh Dtsch Ges Inn Med. 1973;79:1291-3.
4
Effect of halofenate on serum uric acid.卤芬酯对血清尿酸的影响。
Clin Pharmacol Ther. 1973 May-Jun;14(3):371-3. doi: 10.1002/cpt1973143371.
5
Effect of halofenate on serum lipids.
Clin Pharmacol Ther. 1973 May-Jun;14(3):358-65. doi: 10.1002/cpt1973143358.
6
Studies of the uricosuric action of the hypolipidemic drug halofenate.
Clin Pharmacol Ther. 1973 Jul-Aug;14(4):547-51. doi: 10.1002/cpt1973144part1547.
7
Comparative study of several hypolipidemic agents related to clofibrate.几种与氯贝丁酯相关的降血脂药物的比较研究。
Atherosclerosis. 1974 Sep-Oct;20(2):141-53. doi: 10.1016/0021-9150(74)90001-x.
8
The metabolic spectrum of halofenate.
Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):239-43.
9
Long-term efficacy of halofenate on serum triglyceride levels.
Curr Ther Res Clin Exp. 1975 Dec;18(6):855-61.
10
Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
Atherosclerosis. 1975 May-Jun;21(3):391-9. doi: 10.1016/0021-9150(75)90051-9.
Zotero 插件